Navigation Links
A Newly Identified Immunosuppressive Protein in Rheumatoid Arthritis

A complex autoimmune disease, rheumatoid arthritis (RA) is characterized by chronic inflammation and progressive joint damage. This process begins with hyperplasia//, or excessive increase in size and thickness, of synovial tissue. Along with provoking cartilage and bone destruction, this abnormal tissue growth is resistant to apoptosis, the natural cell death vital to the generation of healthy new cells.

Decoy receptor 3 (DcR3) is a newly identified member of the tumor necrosis factor receptor (TNFR) superfamily. A soluble protein, it is overexpressed in tumor cells, including lung and colon cancers, gastrointestinal tract tumors, and leukemia. It is also expressed in a variety of normal tissue—the colon, lung, stomach, spleen, lymph node, pancreas, and spinal cord. Because rheumatoid synovial cells share traits with tumor cells—both are resistant to apoptosis, both proliferate aggressively— DcR3 might play a role in the destructive course of RA. To investigate this possibility, researchers at Kobe University School of Medicine in Japan conducted the first study of DcR3 expression in RA fibroblast-like synoviocytes (FSL)—cells in the synovial membrane instrumental to the production of cartilage as well as synovial fluid. Featured in the April 2007 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), their findings expose DcR3 as one of the factors culpable for RA's hallmark hyperplasia and its crippling consequences.

For their novel study of DcR3, the researchers isolated and cultured FLS from 19 patients with RA, obtained during total knee replacement surgery. For comparison, FLS was also extracted in a similar manner from 14 patients with osteoarthritis (OA). For all samples, expression of DcR3 in FLS was measured by reverse-transcriptase-polymerase chain reaction and Western blotting. Then, apoptosis was induced by Fas, a protein ligand and member of the tumor necrosis factor (TNF) family. Finally, FLS we re incubated with the proinflammatory TNFá prior to Fas-induced apoptosis, and apoptosis was measured.

DcR3 was expressed in both the RA and OA FLS, with no significant quantitative differences found between the samples. However, TNFá increased DcR3 expression in and inhibited Fas-induced apoptosis in RA FLS, but not in OA FLS.

This study affirms DcR3 as an immunosuppressive agent that actually protects destructive rheumatoid synovial cells against death. "We suggest that DcR3 expressed in RA FLS is increased by TNFá, making it one of the pathologic factors that induces hyperplasia of rheumatoid synovium," states researcher and author, Dr. Yasushi Miura. "Thus, strategies aimed at down-regulation of DcR3 in FLS warrant further investigation as a possible therapeutic approach in RA."

Even in this era of TNF-alpha inhibitors and other powerful drugs, there are constantly new aspects of biology being found that offer different forms of treatments for rheumatoid arthritis.

Source-Eurekalert'"/>




Related medicine news :

1. Obesity The Major Cause Of The Increase In Newly Diagnosed Diabetes
2. Newly Identified Strains Of Chlamydia Trachomatis – A Gateway To New Disease
3. Newly Cloned Wheat Gene May Boosts Foods Nutrient Contents – Says A Researc
4. Newly Discovered Immune Defense May Be Impaired In CF Airways
5. Differences Between BP Medicines and Newly-Diagnosed Diabetes Identified
6. Moratorium Proposed on Advertisements of Newly Approved Drugs
7. Potential New Cancer Gene Identified
8. Alcohol Dependence Gene Identified
9. More Causes of Bladder Cancer Identified
10. Dyslexia Gene Identified and Called "KIAA0319"
11. New Enzyme Identified For Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2017)... ... ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® or ... a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance of ... Dr. Bedich offers a variety of cosmetic dentistry services at his practice that are ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... reproductive tract in which the endometrial lining of the uterus spreads into ... pain. Patients experiencing painful intercourse, painful periods, pelvic pain, or irregular bleeding ...
(Date:5/24/2017)... NY (PRWEB) , ... May 24, 2017 , ... ... the practice is offering holistic pediatric dentistry options for its patients on Long ... of the patient’s entire physical well being, and is one of the biggest ...
(Date:5/24/2017)... ... 2017 , ... Technique, technique, technique – with a dash of common sense. ... training and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional pain ... Chang says. “Improper technique in lifting anything heavy or an attempt to lift too ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network ... The Alexis Joy D’Achille Center for Women’s Behavioral Health at West Penn Hospital ... western Pennsylvania for women suffering from pregnancy-related depression. Construction of the Center is ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
Breaking Medicine Technology: